Comparison of in vitro P-glycoprotein screening assays: Recommendations for their use in drug discovery

Journal of Medicinal Chemistry

Volumn 46, Issue 9, 2003, Pages 1716-1725

  Schwab, Dietmar ^a   Fischer, Holger ^a   Tabatabaei, Ali ^b   Poli, Sonia ^a   Huwyler, Jörg ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b ROCHE BIOSCIENCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ASTEMIZOLE; CALCEIN; CIMETIDINE; CLOTRIMAZOLE; COLCHICINE; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DEXAMETHASONE; DIGOXIN; ENKEPHALIN; ERYTHROMYCIN; ETOPOSIDE; GLYCOPROTEIN P; HYDROCORTISONE; ITRACONAZOLE; IVERMECTIN; KETOCONAZOLE; MIBEFRADIL; MICONAZOLE; MIDAZOLAM; MORPHINE; NELFINAVIR; NICARDIPINE; PIMOZIDE; QUINIDINE; RANITIDINE; RHODAMINE 123; UNINDEXED DRUG;

ANIMAL CELL; ARTICLE; DRUG ABSORPTION; DRUG DISPOSITION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; FLUORESCENT ANTIBODY TECHNIQUE; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN DETERMINATION; PROTEIN TRANSPORT; SCREENING; TRANSCYTOSIS;

ADENOSINE TRIPHOSPHATASES; ANIMALS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DRUG EVALUATION, PRECLINICAL; FLUORESCEINS; FLUORESCENT DYES; HUMANS; INDICATORS AND REAGENTS; MICE; MODELS, MOLECULAR; P-GLYCOPROTEIN; RHODAMINES; SPECIES SPECIFICITY; SWINE;

EID: 0037464458     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm021012t     Document Type: Article

References (67)

1. Klein, I.; Sarkadi, B.; Varadi, A. An inventory of the human ABC proteins. Biochim. Biophys. Acta 1999, 1461, 237-262.
2. Ueda, K.; Clark, D. P.; Chen, C. J.; Roninson, I. B.; Gottesman, M. M.; Pastan, I. The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J. Biol. Chem. 1987, 262, 505-8.
3. Devault, A.; Gros, P. Two members of the mouse mdr gene family confer multidrug resistance with overlapping but distinct drug specificities. Mol. Cell Biol. 1990, 10, 1652-1663.
4. Seelig, A. A general pattern for substrate recognition by Pglycoprotein. Eur. J. Biochem. 1998, 251, 252-261.
5. Fojo, A. T.; Ueda, K.; Slamon, D. J.; Poplack, D. G.; Gottesman, M. M.; Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 265-9.
6. Thiebaut, F.; Tsuruo, T.; Hamada, H.; Gottesman, M. M.; Pastan, I.; Willingham, M. C. Cellular localization of the multidrugresistance gene product P-glycoprotein in normal human tissue. Proc. Natl. Acad. Sci. 1987, 84, 7735-7738.
7. Tsuji, A.; Terasaki, T.; Takabatake, Y.; Tenda, Y.; Tamai, I.; Yamashiba, T.; Moritani, S.; Tsuruo, T.; Yamashita, J. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci. 1992, 51, 1427-1437.
8. Schinkel, A. H.; Mayer, U.; Wagenaar, E.; Mol, C. A.; van Deemter, L.; Smit, J. J.; van der Valk, M. A.; Voordouw, A. C.; Spits, H.; van Tellingen, O.; Zijlmans, J. M.; Fibbe, W. E.; Borst, P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4028-4033.
9. Sikic, B. I. Pharmacologic approaches to reversing multidrug resistance. Semin. Hematol. 1997, 34, 40-7.
10. Zhang, Y.; Benet, L. Z. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin. Pharmacokinet. 2001, 40, 159-168.
11. Schinkel, A. H. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 1999, 36, 179-194.
12. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H. P.; Brockmoller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 34733478.
13. Kim, R. B.; Leake, B. F.; Choo, E. F.; Dresser, G. K.; Kubba, S. V.; Schwarz, U. I.; Taylor, A.; Xie, H. G.; McKinsey, J.; Zhou, S.; Lan, L. B.; Schuetz, J. D.; Schuetz, E. G.; Wilkinson, G. R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001, 70, 189-199.
14. Sakaeda, T.; Nakamura, T.; Horinouchi, M.; Kakumoto, M.; Ohmoto, N.; Sakai, T.; Morita, Y.; Tamura, T.; Aoyama, N.; Hirai, M.; Kasuga, M.; Okumura, K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001, 18, 1400-1404.
15. Yu, D. K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 1999, 39, 12031211.
16. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H. P.; von Richter, O.; Zundler, J.; Kroemer, H. K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104, 147-153.
17. Madsen, J. K.; Jensen, J. D.; Jensen, L. W.; Pedersen, E. B. Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine. Eur. J. Clin. Pharmacol. 1996, 50, 203-208.
18. Yeleswaram, K. Comment on "Pharmacokinetic interaction between cyclosporine and the dihydropyridine calcium antagonist felodipine". Eur. J. Clin. Pharmacol. 1997, 52, 159/161.
19. Rodin, S. M.; Johnson, B. F. Pharmacokinetic interactions with digoxin. Clin. Pharmacokinet. 1988, 15, 227-244.
20. Dalton, W. S. Is p-glycoprotein a potential target for reversing clinical drug resistance? Curr. Opin. Oncol. 1994, 6, 595-600.
21. Advani, R.; Saba, H. I.; Tallman, M. S.; Rowe, J. M.; Wiernik, P. H.; Ramek, J.; Dugan, K.; Lum, B.; Villena, J.; Davis, E.; Paietta, E.; Litchman, M.; Sikic, B. I.; Greenberg, P. L. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar). Blood 1999, 93, 787-795.
22. Hsu, A.; Granneman, G. R.; Bertz, R. J. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin. Pharmacokinet. 1998, 35, 275-291.
23. Gisslen, M.; Hagberg, L. Antiretroviral treatment of central nervous system HIV-1 infection: a review. HIV Med. 2001, 2, 97-104.
24. Yamazaki, M.; Neway, W. E.; Ohe, T.; Chen, I.; Rowe, J. F.; Hochman, J. H.; Chiba, M.; Lin, J. H. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 2001, 296, 723-735.
25. Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm. Res. 2001, 18, 1660-1668.
26. Jonker, J. W.; Wagenaar, E.; van Deemter, L.; Gottschlich, R.; Bender, H. M.; Dasenbrock, J.; Schinkel, A. H. Role of bloodbrain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br. J. Pharmacol. 1999, 127, 43-50.
27. Chen, C.; Pollack, G. M. Enhanced antinociception of the model opioid peptide [D-penicillamine] enkephalin by P-glycoprotein modulation. Pharm. Res. 1999, 16, 296-301.
28. Letrent, S. P.; Pollack, G. M.; Brouwer, K. R.; Brouwer, K. L. Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm. Res. 1998, 15, 599-605.
29. Smith, B. J.; Doran, A. C.; McLean, S.; Tingley, F. D., III; O'Neill, B. T.; Kajiji, S. M. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. J. Pharmacol. Exp. Ther. 2001, 298, 1252-1259.
30. Sarkadi, B.; Price, E. M.; Boucher, R. C.; Germann, U. A.; Scarborough, G. A. Expression of the human multidrug resistance cDNA in insect cells generates a high activity drugstimulated membrane ATPase. J. Biol. Chem. 1992, 267, 4854-4858.
31. Urbatsch, I. L.; al, S. M.; Senior, A. E. Characterization of the ATPase activity of purified Chinese hamster P-glycoprotein. Biochemistry 1994, 33, 7069-7076.
32. Nelson, E. J.; Zinkin, N. T.; Hinkle, P. M. Fluorescence methods to assess multidrug resistance in individual cells. Cancer Chemother. Pharmacol. 1998, 42, 292-299.
33. Wang, E. J.; Casciano, C. N.; Clement, R. P.; Johnson, W. W. Active transport of fluorescent p-glycoprotein substrates: evaluation as markers and interaction with inhibitors. Biochem. Biophys. Res. Commun. 2001, 289, 580-585.
34. Eytan, G. D.; Regev, R.; Oren, G.; Hurwitz, C. D.; Assaraf, Y. G. Efficiency of P-glycoprotein-mediated exclusion of rhodamine dyes from multidrug-resistant cells is determined by their passive transmembrane movement rate. Eur. J. Biochem. 1997, 248, 104-112.
35. Tiberghien, F.; Loor, F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-cancer Drugs 1996, 7, 568-578.
36. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W. D. Competitive, noncompetitive and cooperative interactions between substrates of P-glycoprotein as measured by its ATPase activity. Biochim. Biophys. Acta 1997, 1361, 169-76.
37. Pascaud, C.; Garrigos, M.; Orlowski, S. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents. Biochem. J. 1998, 333, 351-358.
38. Dey, S.; Ramachandra, M.; Pastan, I.; Gottesman, M. M.; Ambudkar, S. V. Evidence for two nonidentical drug-interaction sites in the human P-glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 10594-10599.
39. Shapiro, A. B.; Ling, V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiol. Scand. Suppl. 1998, 643, 227-234.
40. Korzekwa, K. R.; Krishnamachary, N.; Shou, M.; Ogai, A.; Parise, R. A.; Rettie, A. E.; Gonzalez, F. J.; Tracy, T. S. Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 1998, 37, 4137-4147.
41. Tang-Wai, D. F.; Kajiji, S.; DiCapua, F.; de Graaf, D.; Roninson, I. B.; Gros, P. Human (MDR1) and mouse (mdr1, mdr3) Pglycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry 1995, 34, 32-39.
42. Schinkel, A. H.; Wagenaar, E.; Mol, C. A.; van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97, 2517-2524.
43. Sharom, F. J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol. 1997, 160, 161-175.
44. Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Huang, L.; Morgan, J. B.; Webster, L. O.; Serabjit-Singh, C. S. Rational use of in vitro p-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 2001, 299, 620-628.
45. Doppenschmitt, S.; Spahn-Langguth, H.; Regardh, C. G.; Langguth, P. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein. J. Pharm. Sci. 1999, 88, 1067-1072.
46. Smit, J. W.; Weert, B.; Schinkel, A. H.; Meijer, D. K. Heterologous expression of various P-glycoproteins in polarized epithelial cells induces directional transport of small (type 1) and bulky (type 2) cationic drugs. J. Pharmacol. Exp. Ther. 1998, 286, 321-327.
47. Huwyler, J.; Drewe, J.; Klusemann, C.; Fricker, G. Evidence for P-glycoprotein modulated penetration of morphine-6-glucuronide into brain capillary endothelium. Br. J. Pharmacol. 1996, 118, 1879-1885.
48. Eneroth, A.; Astrom, E.; Hoogstraate, J.; Schrenk, D.; Conrad, S.; Kauffmann, H. M.; Gjellan, K. Evaluation of a vincristine resistant Caco-2 cell line for use in a calcein AM extrusion screening assay for P-glycoprotein interaction. Eur. J. Pharm. Sci. 2001, 12, 205-214.
49. Wacher, V. J.; Wu, C. Y.; Benet, L. Z. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Clin. Pharmacol. Ther. 1995, 58, 15-19.
50. Kim, R. B.; Wandel, C.; Leake, B.; Cvetkovic, M.; Fromm, M. F.; Dempsey, P. J.; Roden, M. M.; Belas, F.; Chaudhary, A. K.; Roden, D. M.; Wood, A. J.; Wilkinson, G. R. Interrelationship between substrates and inhibitors of human CYP3A and P- glycoprotein. Pharm. Res. 1999, 16, 408-414.
51. Franke, H.; Galla, H.; Beuckmann, C. T. Primary cultures of brain microvessel endothelial cells: a valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res. Protoc. 2000, 5, 248-256.
52. Schinkel, A. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; Borst, P. Absence of the mdr1a P-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J. Clin. Invest. 1995, 96, 1698-1705.
53. Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E. G.; Lan, L. B.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 2002, 61, 974-981.
54. Crespi, C. L.; Miller, V. P.; Penman, B. W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Anal. Biochem. 1997, 248, 188-190.
55. Eytan, G. D.; Kuchel, P. W. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cytol. 1999, 190, 175-250.
56. Jalava, K. M.; Partanen, J.; Neuvonen, P. J. Itraconazole decreases renal clearance of digoxin. Ther. Drug Monit. 1997, 19, 609-613.
57. Kawahara, M.; Sakata, A.; Miyashita, T.; Tamai, I.; Tsuji, A. Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice. J. Pharm. Sci. 1999, 88, 1281-1287.
58. Masereeuw, R.; Moons, M. M.; Russel, F. G. Rhodamine 123 accumulates extensively in the isolated perfused rat kidney and is secreted by the organic cation system. Eur. J. Pharmacol. 1997, 321, 315-323.
59. van der Sandt, I. C.; Blom-Roosemalen, M. C.; de Boer, A. G.; Breimer, D. D. Specificity of doxorubicin versus rhodamine-123 in assessing P- glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines. Eur. J. Pharm. Sci. 2000, 11, 207-214.
60. Drewe, J.; Gutmann, H.; Fricker, G.; Török, M.; Beglinger, C.; Huwyler, J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analogue SDZ 833. Biochem. Pharmacol. 1999, 57, 1147-1152.
61. Litman, T.; Zeuthen, T.; Skovsgaard, T.; Stein, W. D. Structure-activity relationships of P-glycoprotein interacting drugs: kinetic characterization of their effects on ATPase activity. Biochim Biophys Acta 1997, 1361, 159-168.
62. Lentz, K. A.; Polli, J. W.; Wring, S. A.; Humphreys, J. E.; Polli, J. E. Influence of passive permeability on apparent P-glycoprotein kinetics. Pharm. Res. 2000, 17, 1456-1460,
63. Sandstrom, R.; Karlsson, A.; Knutson, L.; Lennernas, H. Jejunal absorption and metabolism of R/S-verapamil in humans. Pharm. Res. 1998, 15, 856-862.
64. Kim, R. B.; Fromm, M. F.; Wandel, C.; Leake, B.; Wood, A. J.; Roden, D. M.; Wilkinson, G. R. The drug transporter Pglycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998, 101, 289-294.
65. Drion, N.; Risede, P.; Cholet, N.; Chanez, C.; Scherrmann, J. M. Role of P-170 glycoprotein in colchicine brain uptake. J. Neurosci. Res. 1997, 49, 80-88.
66. Schinkel, A. H.; Smit, J. J. M.; van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; van Deemter, L.; Mol, C. A. A. M.; van der Valk, M. A.; Robanus-Maandag, E. C.; te Riele, H. P. J.; Berns, A. J. M.; Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
67. Schwarz, U. I.; Gramatte, T.; Krappweis, J.; Oertel, R.; Kirch, W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int. J. Clin. Pharmacol. Ther. 2000, 38, 161-167.